Cargando…
Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
INTRODUCTION: Cell-based therapy represents a new frontier in the treatment of a wide variety of human diseases traditionally associated with morbidity outcomes, including those involving inflammation, autoimmunity, tissue damage, and cancer. However, the use of mesenchymal stem cells (MSCs) to trea...
Autores principales: | Atsuta, Ikiru, Liu, Shiyu, Miura, Yasuo, Akiyama, Kentaro, Chen, Chider, An, Ying, Shi, Songtao, Chen, Fa-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854680/ https://www.ncbi.nlm.nih.gov/pubmed/24025590 http://dx.doi.org/10.1186/scrt322 |
Ejemplares similares
-
Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression
por: Chen, Chider, et al.
Publicado: (2014) -
Fas–Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis
por: Volpe, Elisabetta, et al.
Publicado: (2016) -
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
Publicado: (1996) -
Hydrogen sulfide promotes immunomodulation of gingiva-derived mesenchymal stem cells via the Fas/FasL coupling pathway
por: Yang, Ruili, et al.
Publicado: (2018) -
Impairment of Fas-ligand–caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death
por: Glukhova, Xenia A., et al.
Publicado: (2018)